
Annual report 2022
added 12-21-2024
Genetron Holdings Limited Financial Statements 2011-2025 | GTH
Annual Financial Statements Genetron Holdings Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
- | 1.54 B | 1.66 B | 250 M | 60.1 M | 116 M | - | - | - | - | - | - |
Shares |
- | 461 M | 67.7 M | 67.7 M | 69.1 M | 67.7 M | - | - | - | - | - | - |
Historical Prices |
0.87 | 3.35 | 24.6 | - | - | - | - | - | - | - | - | - |
Net Income |
- | -503 M | -3.07 B | -676 M | -465 M | -421 M | - | - | - | - | - | - |
Revenue |
651 M | 532 M | 424 M | 323 M | 225 M | 101 M | - | - | - | - | - | - |
Cost of Revenue |
- | 194 M | 164 M | 178 M | 132 M | - | - | - | - | - | - | - |
Gross Profit |
281 M | 338 M | 260 M | 145 M | 92.7 M | 26.8 M | - | - | - | - | - | - |
Operating Income |
- | -518 M | -268 M | -307 M | -233 M | - | - | - | - | - | - | - |
EBITDA |
- | -518 M | -268 M | -307 M | -233 M | -134 M | - | - | - | - | - | - |
Operating Expenses |
983 M | 856 M | 529 M | 452 M | 326 M | 181 M | - | - | - | - | - | - |
General and Administrative Expenses |
- | - | 126 M | 117 M | 88.2 M | 45.5 M | - | - | - | - | - | - |
All numbers in CNY currency
Quarterly Income Statement Genetron Holdings Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|
All numbers in CNY currency
Main types of financial statements Genetron Holdings Limited GTHFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Genetron Holdings Limited plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
$ 0.33 | -6.23 % | $ 30.6 M | ||
|
Fluidigm Corporation
FLDM
|
$ 3.75 | 1.08 % | $ 308 M | ||
|
Global Cord Blood Corporation
CO
|
$ 2.99 | - | $ 399 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
$ 21.99 | - | $ 562 M | ||
|
Chembio Diagnostics
CEMI
|
$ 0.46 | 0.22 % | $ 16.8 M | ||
|
Pacific Biosciences of California
PACB
|
$ 1.97 | -5.74 % | $ 500 M | ||
|
Koninklijke Philips N.V.
PHG
|
$ 27.3 | -5.5 % | $ 20 B | ||
|
Meridian Bioscience
VIVO
|
$ 33.97 | - | $ 1.49 B | ||
|
HTG Molecular Diagnostics
HTGM
|
$ 0.48 | -20.0 % | $ 1.06 M | ||
|
Quotient Limited
QTNT
|
$ 0.32 | -11.32 % | $ 1.1 M | ||
|
Bioventus
BVS
|
$ 6.94 | 3.43 % | $ 435 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
$ 165.21 | - | $ 10.7 B | ||
|
Thermo Fisher Scientific
TMO
|
$ 557.63 | -1.09 % | $ 213 B | ||
|
Trinity Biotech plc
TRIB
|
$ 1.0 | -1.96 % | $ 61.9 M | ||
|
Heska Corporation
HSKA
|
$ 119.99 | - | $ 1.31 B | ||
|
Twist Bioscience Corporation
TWST
|
$ 33.57 | -1.78 % | $ 1.95 B | ||
|
Motus GI Holdings
MOTS
|
$ 0.17 | -34.28 % | $ 263 K | ||
|
Biocept
BIOC
|
$ 0.43 | -13.05 % | $ 7.29 M | ||
|
Syneos Health
SYNH
|
$ 42.98 | - | $ 4.46 B | ||
|
Invitae Corporation
NVTA
|
$ 0.09 | - | $ 21.2 M | ||
|
DermTech
DMTK
|
$ 0.09 | -11.32 % | $ 2.94 M | ||
|
Akumin
AKU
|
$ 0.29 | -17.87 % | $ 25.9 M | ||
|
Castle Biosciences
CSTL
|
$ 24.15 | 0.79 % | $ 671 M | ||
|
DarioHealth Corp.
DRIO
|
$ 15.33 | -2.67 % | $ 435 M | ||
|
Exagen
XGN
|
$ 11.89 | -0.17 % | $ 210 M | ||
|
PerkinElmer
PKI
|
$ 115.24 | -0.91 % | $ 14.7 B | ||
|
OpGen
OPGN
|
$ 1.96 | -16.95 % | $ 1.54 M | ||
|
DexCom
DXCM
|
$ 69.23 | -1.98 % | $ 26.7 B | ||
|
Organovo Holdings
ONVO
|
$ 2.12 | -2.3 % | $ 19.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
$ 12.26 | 4.79 % | $ 130 M | ||
|
Danaher Corporation
DHR
|
$ 216.9 | -1.86 % | $ 159 B | ||
|
Quidel Corporation
QDEL
|
$ 28.19 | -4.38 % | $ 1.19 B | ||
|
Neogen Corporation
NEOG
|
$ 6.16 | -0.81 % | $ 1.34 B | ||
|
Biomerica
BMRA
|
$ 2.93 | -1.15 % | $ 6.73 M | ||
|
Fulgent Genetics
FLGT
|
$ 23.43 | 0.51 % | $ 708 M | ||
|
Psychemedics Corporation
PMD
|
$ 2.67 | -1.84 % | $ 15.3 M | ||
|
Genetic Technologies Limited
GENE
|
$ 0.77 | - | $ 7.1 B | ||
|
Myriad Genetics
MYGN
|
$ 8.13 | 0.37 % | $ 737 M | ||
|
Renalytix AI plc
RNLX
|
$ 0.21 | 5.66 % | $ 22.7 M | ||
|
Medpace Holdings
MEDP
|
$ 580.53 | -2.67 % | $ 18 B | ||
|
IQVIA Holdings
IQV
|
$ 218.13 | 0.32 % | $ 39.5 B | ||
|
CareDx, Inc
CDNA
|
$ 14.67 | 1.1 % | $ 789 M | ||
|
Brainsway Ltd.
BWAY
|
$ 16.59 | -2.5 % | $ 99.4 M | ||
|
Biodesix
BDSX
|
$ 6.55 | -1.5 % | $ 849 M | ||
|
T2 Biosystems
TTOO
|
$ 0.12 | -39.35 % | $ 313 K | ||
|
Guardant Health
GH
|
$ 69.58 | -1.79 % | $ 8.54 B | ||
|
Agilent Technologies
A
|
$ 145.85 | -0.5 % | $ 44.3 B | ||
|
Co-Diagnostics
CODX
|
$ 0.57 | -54.76 % | $ 16.7 M | ||
|
Lantheus Holdings
LNTH
|
$ 57.33 | -1.38 % | $ 3.97 B |